SCHEMBL6887018

SCHEMBL6887018

CC(I)OC(=O)Oc1ccc(C(C)(C)C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
TDP1 Q9NUW8 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.47
RAB9A P51151 3/20 0.45
NPC1 O15118 1/20 0.45
HTT P42858 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
NPSR1 Q6W5P4 2/20 0.44
ALDH1A1 P00352 2/20 0.42
THRB P10828 1/20 0.42
PRSS1 P07477 1/20 0.41
ACR P10323 1/20 0.41
TRPV1 Q8NER1 1/20 0.41
HSD17B10 Q99714 2/20 0.41
LMNA P02545 1/20 0.41
ALOX15 P16050 1/20 0.41
APEX1 P27695 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1792450 0.83 MAPT (0.49) MAPTTDP1L3MBTL1SMN1; SMN2RAB9A
SCHEMBL21546150 0.82 MAPT (0.47) MAPTTDP1L3MBTL1SMN1; SMN2RAB9A
SCHEMBL47809 0.82 MAPT (0.61) MAPTTDP1L3MBTL1SMN1; SMN2RAB9A
SCHEMBL6890875 0.81 SMN1; SMN2 (0.45) SMN1; SMN2RAB9ANPC1HTTMEN1
SCHEMBL6895467 0.81 LMNA (0.52) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL1792448 0.81 SMN1; SMN2 (0.49) MAPTTDP1L3MBTL1SMN1; SMN2RAB9A
SCHEMBL1790162 0.80 MAPT (0.56) MAPTTDP1L3MBTL1SMN1; SMN2RAB9A
SCHEMBL6895672 0.79 ALDH1A1 (0.42) MAPTTDP1L3MBTL1RAB9ANPC1
SCHEMBL1790341 0.78 MAPT (0.55) MAPTTDP1L3MBTL1SMN1; SMN2RAB9A
SCHEMBL13712844 0.78 MAPT (0.58) MAPTTDP1L3MBTL1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
US-6458780-B1 IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND MEIJI SEIKA KAISHA, LTD. (JP) 2002-10-01 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 MAPT 4427/4885TDP1 3544/4885L3MBTL1 2671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.